DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
 Print  Email    

Amarin Corporation PLC (AMRN) Announces FDA Advisory Committee Will Not Be Scheduled in Connection With New Drug Application for AMR101


2/13/2012 10:13:07 AM

BEDMINSTER, N.J. and DUBLIN, Ireland, Feb. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a late-stage biopharmaceutical company with a focus on cardiovascular disease, announced today that it was informed by the U.S. Food and Drug Administration (FDA) that no advisory committee meeting will be scheduled in connection with the FDA's review of the New Drug Application (NDA) seeking approval for the use AMR101 in the treatment of patients with very high triglycerides (=500mg/dL), the company's lead product candidate. The FDA has previously assigned a Prescription Drug User Fee Act (PDUFA) date of July 26, 2012 for completion of its review of the AMR101 NDA.

Read at GlobeNewswire


 Read Article at  Related Companies  News Categories
   


ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 
    

//-->